Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy

Yaakob, Che Anuar Che; Abdullah, Abu Dzarr; Ismail, Ahmad Amir; Lah, Nik Ahmad Zuky Nik; Ho, Jacqueline J

doi:10.1002/14651858.cd007801

Cited by 4 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3,6,8,9]. Although a few systematic and narrative reviews have tried to assess the risk-benefit profile of anticoagulant treatment of VTE in pregnancy [3,[9][10][11], these studies have often mixed together data from patients receiving anticoagulant therapy for different indications, such as VTE treatment or prophylaxis, prevention of obstetric complications, and prevention of arterial thrombosis in patients with mechanical cardiac valves, or, conversely, have focused on only a single therapeutic agent.…”

Section: Introductionmentioning

confidence: 99%

Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta‐analysis of the literature

Romualdi

Dentali

Rancan

et al. 2013

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

To cite this article: Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S, Ageno W. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2013; 11: 270-81.Summary. Venous thromboembolism (VTE) is one of the most relevant causes of maternal death in industrialized countries. Low molecular weight heparin (LMWH), continued throughout the entire pregnancy and puerperium, is currently the preferred treatment for patients with acute VTE occurring during pregnancy. However, information on the efficacy and safety of anticoagulant drugs in this setting is extremely limited. We carried out a systematic review and a meta-analysis of the literature to provide an estimate of the risk of bleeding complications and VTE recurrence in patients with acute VTE during pregnancy treated with antithrombotic therapy. The weight mean incidence (WMI) of bleeding and thromboembolic events and the corresponding 95% confidence interval (CI) were calculated. Eighteen studies, giving a total of 981 pregnant patients with acute VTE, were included. LMWH was prescribed to 822 patients; the remainder were treated with unfractionated heparin. Anticoagulant therapy was associated with WMIs of major bleeding of 1.41% (95% CI 0.60-2.41%; I) antenatally and 1.90% (95% CI 0.80-3.60%) during the first 24 h after delivery. The estimated WMI of recurrent VTE during pregnancy was 1.97% (95% CI 0.88-3.49%; I 2 39.5%). Anticoagulant therapy appears to be safe and effective for the treatment of pregnancy-related VTE, but the optimal dosing regimens remain uncertain.

show abstract

Section: Introductionmentioning

confidence: 99%

Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta‐analysis of the literature

Romualdi

Dentali

Rancan

et al. 2013

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…En este sentido, se ha publicado una revisión sistemática de Cochrane en el 2014, que tuvo por objetivo comparar eficacia entre Heparina de bajo peso molecular (HBPM), heparina no fraccionada (HNF) y warfarina en TVP en el embarazo, donde se concluyó que no se disponían de estudios controlados randomizados 32 . Por ello, el uso de heparinas se sustenta en extrapolaciones de estudios en no embarazadas.…”

Section: Anticoagulación Farmacológica A) ¿Con Qué Fármaco?unclassified

Enfermedad Tromboembólica Venosa en el período grávido puerperal. Diagnóstico, tratamiento y profilaxis.

Irigoin

Lorenzo

Grille

et al. 2021

rumi

View full text Add to dashboard Cite

Venous Thromboembolic Disease in the puerperal gravid period. Diagnosis, treatment and prophylaxis. Doença tromboembólica venosa no período gravídico puerperal. Diagnóstico, tratamento e profilaxia.Resumen: El embarazo y puerperio son situaciones asociadas fisiológicamente con un marcado aumento del riesgo de enfermedad tromboembólica venosa. El riesgo se estima entre 7 a 10 veces superior que en mujeres de igual edad y 15-35 veces superior que la población control, durante el puerperio y hasta la sexta semana post-parto. Los factores de riesgo son distintos durante el período prenatal y post-parto. Los métodos diagnósticos incluyen radiografía, angiotomografía de tórax y centellograma pulmonar ventilación-perfusión, ecodoppler venoso y venografía por resonancia nuclear magnética. El tratamiento supone un desafío que va desde la elección de la droga anticoagulante, los cambios en la farmacocinética durante el embarazo, entre otros. Se presentan algoritmos diagnósticos y terapéuticos.

show abstract

“…Besides, LEDVT is characterized by some secondary complications such as chronic venous insufficiency, chronic pulmonary hypertension, pulmonary thromboembolism, and recurrent thrombosis, resulting in a high morbidity and mortality . Various diagnostic tests are included in DVT diagnosis such as Doppler ultrasound, X‐ray venography, and D‐Dimer (D‐D) . Anticoagulation, thrombolysis, and low molecular weight heparins are usually adopted in treating DVT with anticoagulation as the mainstay of treatment …”

Section: Introductionmentioning

confidence: 99%

“…7 Various diagnostic tests are included in DVT diagnosis such as Doppler ultrasound, X-ray venography, and D-Dimer (D-D). 8 Anticoagulation, thrombolysis, and low molecular weight heparins are usually adopted in treating DVT with anticoagulation as the mainstay of treatment. 9 As one of the vitamin K-dependent single-chain glycoprotein, coagulation factor VII (FVII) is activated to respond to vascular or tissue injury.…”

Section: Introductionmentioning

confidence: 99%

Genetic polymorphisms in the FVII gene is associated with lower extremity deep venous thrombosis: A case‐control study

Liu¹,

Chen

2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

This study aims to explore the associations between FVII gene polymorphisms (R353Q, 5'F7, and -402G/A) and lower extremity deep venous thrombosis (LEDVT) in a Chinese Han population. LEDVT patients (153) and healthy people (174) were, respectively, as case and control groups and evaluated related biochemical indicators. Gene polymorphisms of R353Q, 5'F7, and -402G/A of FVII, serum FVII level, antithrombin activity, plasma fibrinogen content, and plasma D-dimer (D-D) level were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), ELISA, chromogenic substrate assay, coagulating assay, and Immunoturbidimetry assay, respectively. Compared with the control group, the case group had a higher level of body mass index (BMI), glucose, and fibrinogen, and lower level of total cholesterol (TC). Notable differences were found in GG genotype, G and A alleles, as well as distribution of recessive model of -402G/A. The serum FVII level of GG genotype was higher than that of GA and AA genotypes. FIB and D-D had a higher level had a lower level in GG genotype when compared with GA and AA genotypes. Smoking, drinking, serum FVII level, and -402G/A-GG were the independent risk factors for LEDVT. This study demonstrates that -402G/A of FVII may be a risk factor for LEDVT patients in a Chinese Han population.

show abstract

Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy

Cited by 4 publications

References 10 publications

Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta‐analysis of the literature

Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta‐analysis of the literature

Enfermedad Tromboembólica Venosa en el período grávido puerperal. Diagnóstico, tratamiento y profilaxis.

Genetic polymorphisms in the FVII gene is associated with lower extremity deep venous thrombosis: A case‐control study

Contact Info

Product

Resources

About